retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 CKD Diet Tips: Balancing hsv1 Pack Type:Canister (25 servings)

retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 CKD Diet Tips: Balancing hsv1 Pack Type:Canister (25 servings)

CKD Diet Tips: Balancing Protein, Potassium & Phosphorus

Key readouts include: TRIUMPH-1 (obesity): Participants on the 12 mg weekly dose achieved an average body-weight reduction of roughly 28.3% at 80 weeks and up to 30.3% at 104 weeks , figures that approach outcomes previously associated only with bariatric surgery

hsv1

Pack Type:Canister (25 servings)

Data analysed by one-way ANOVA, multiple comparison, Bonferroni post hoc test ( c , e , g , l , n , p , v , x and z ) and two-way repeated measures ANOVA to assess main effects of treatment ( i , j , q , s and t )